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ABSTRACT 
Background: Scientific data provide today the evidence that secondary K-RAS mutations do not 
occur during anti-EGFR therapy in CRC patients. This multicenter phase II prospective study aims 
to investigate the activity of a retreatment with a cetuximab-based therapy.  Patients and Methods: 
we enrolled 39 irinotecan refractory patients who had a clinical benefit after a line of Cetuximab 
plus irinotecan-based therapy and then a progression of disease for which underwent a new line 
chemotherapy and finally, after a clear new progression of disease, were re-treated with the same 
Cetuximab plus Irinotecan based therapy. Results: Median number of therapeutic lines before 
accrual was 4. Median interval time between last cycle of first cetuximab-based therapy and first 
cycle of the retreatment was 6 months. Overall response rate was 53.8% with 19 partial responses 
(48.7%) and 2 complete responses (5.1%). Disease stabilization was obtained in 35.9% of patients 
and progression in 4 patients (10.2%). Median time to progression was 6.6 months. The correlation 
between skin toxicity during first cetuximab therapy and during cetuximab rechallenge was 
significant (p= .01). Conclusions: Rechallenge with the same cetuximab-based therapy may 
achieve a new important clinical benefit further delaying the progression of disease and improving 
the therapeutic options. 
 
 4 
 
INTRODUCTION 
Cetuximab (ERBITUX®) is a chimeric IgG1 monoclonal antibody that bind extracellular domain of 
epidermal growth factor receptor (EGFR)
1
 preventing its linkage with endogenous ligands such as 
TGF-α and EGF. Several phase II and phase III trials supported cetuximab combination in first-line 
treatment of metastatic colorectal cancer (mCRC) reporting a clinical benefit, progression free 
survival (PFS) and overall response rate (ORR) increase and higher rates of liver resections 
2, 3, 4, 5
. 
Other studies supported the use of cetuximab as a single agent or in combination with irinotecan for 
patients who had progressed on a previous chemotherapy 
6,7,8
. The EGFR activation leads to the 
activation of intracellular effectors involved in intracellular signaling pathways, such as the G 
protein K-ras.  
Moreover oncogene K-ras mutations affect the clinical response to anti-EGFR therapy. In fact a 
large retrospective analysis evaluated K-ras mutation status in 113 patients affected by irinotecan-
refractory mCRC treated with cetuximab with or without irinotecan in clinical trials. An ORR of 
41% was observed in 27 of 66 patients with wild-type (WT) K-ras versus 0 of 42 in K-ras mutated 
patients. The median OS was significantly improved in patients with WT K-ras versus patients with 
mutated K-ras (P = .02). Decrease in tumor sizes was significantly larger in WT K-ras patients
9
. 
Another prospective trial observed that patients whose tumors do not have K-ras mutations have a 
significantly higher DCR than patients with K-ras mutations (P = .0003)
10
. 
Then, other mutations downstream of EGFR could affect its anti-EGFR effectiveness such as 
BRAF, Src
11, 12
, and PI3KCA.  BRAF is a serine-threonine kinase and the principal effector of K-
ras. BRAF mutation (exons 15 and 21) in CRC occurs in  a low percentage of cases (5-12% of 
cases)
13
, but several studies have suggested that it is associated with a decreased response to anti-
EGFR therapy 
14, 15, 16
 .  
PIK3CA is also commonly mutated in colorectal cancer (20% of cases) 
17
. It encodes the p110a 
subunit of PI3K regulating its function. It has been associated with cetuximab resistance in 
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preclinical studies 
18,19
. Moreover PI3KCA mutations have been associated with panitumumab and 
cetuximab resistance in retrospective analyses including patients affected by mCRC 
15
. Loss of 
pTEN protein, a negative regulator of PI3K, has also been associated with resistance to anti-EGFR 
therapy 
20, 21 ,22
.  
K-ras mutation is an early pathogenic step in colorectal cancer development, and it seems to remain 
the same during tumor progression
23
. In fact, the same K-ras mutations can be detected in most 
adenoma and in more than a half of the tumor adjacent mucosa 
24
. One study analyzed K-ras status 
of CRC primary tumor and its metastasis sites in 21 patients. It was observed that anti-EGFR 
therapy do not change K-ras status concordance between CRCs and corresponding metastasis in 20 
of 21 cases 
25
. These data provided first evidence that secondary K-ras mutations do not occur 
during anti-EGFR therapy in CRC patients.  
Basing on the hypothesis that K-ras status remain the same during the history of the disease, despite 
the treatments received, we designed a phase II prospective study with the aim of demonstrating 
that patients who responded and then progressed during a cetuximab-based therapy can receive, 
after a new line of therapy, a further line containing the same cetuximab-based therapy gaining  a 
clinical benefit.  
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MATERIALS AND METHODS 
Eligibility criteria 
This is a multicentric phase II trial that examines irinotecan refractory patients who had a clinical 
benefit (confirmed stable disease for at least 6 months or clinical response) after a line of 
Cetuximab- plus Irinotecan-based therapy and then a progression of disease for which underwent 
a new line chemotherapy and finally, after a clear new progression of disease, were re-treated 
with the same or another Cetuximab plus Irinotecan-based therapy. Eligible patients had 
histologic or cytologic confirmation of CRC, with measurable metastatic disease in at least one 
site identified by instrumental examinations. All patients were required to be K-ras wild type 
(codons 12 and 13) with RT-PCR and K-ras status was centrally assessed.  Patients aged between 
40 and 80 years with an Eastern Cooperative Oncology Group (ECOG) performance status  1 
and a life expectance  3 months were included. Bone marrow function requirements included an 
absolute neutrophil count  1500/mm³, a platelet count  100000/ mm³ and haemoglobin  10.0 
g/100 ml. Preserved renal function (serum creatinine  1.5 mg/dL and normal creatinine 
clearance), hepatic function (total bilirubin  1.5 mg/dL, AST and ALT  2,5 times normal). The 
study has been conducted in accordance with the ethical principles that have their origin in the 
current Declaration of Helsinki and all patients signed a written consent form prior to the 
enrollment. Patients were excluded if adequate follow-up was not possible (environmental or 
geographic difficulties, no compliance to undergo necessary clinical-instrumental investigations, 
etc.). 
Treatment plan 
Cetuximab was given at a loading dose of 400 mg m2 followed by weekly infusions of 
250 mg m-2. Irinotecan was given at dose of 180 mg m2 as a 90 min infusion day. A histamine-
receptor antagonist and Atropine (0.25 mg) were given as premedication before every infusion. 
Moreover, dexamethasone was given at the dose of 20 mg before the induction course and at the 
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dose of 8 mg in the further courses. A standard antiemetic drug was always given in the 
premedication and in the following days according to the physician's opinion. All the patients 
were to be treated until disease progression or unacceptable toxic effects. Tumor response was 
evaluated every 8 weeks with the use of consistent imaging techniques (CT or MRI). The 
response to the treatment, both during cetuximab treatment and rechallenge, prior or further 
treatments, was evaluated centrally by two different radiologists, and confirmed by the 
investigators, according to Response Evaluation Criteria in Solid Tumors (RECIST)
26
. Toxic 
effects were assessed according to the National Cancer Institute Common Toxicity Criteria, 
version 2 (National Cancer Institute Common Toxicity Criteria, 1998).  
Toxicity and Dose Modifications 
Toxic effects were assessed according to the National Cancer Institute Common Toxicity Criteria 
(National Cancer Institute Common Toxicity Criteria, 1998). Modifications of the dose of 
cetuximab were performed only in case of toxic effects to the skin not restoring after 2 weeks of 
rest, and modifications in the dose of irinotecan were made in case of haematologic or 
nonhematologic toxic effects. Cumulative toxicity was evaluated and recorded before each 
treatment cycle. Irinotecan administration was stopped for  G2 hematological toxicity and was 
restarted in case of toxicity regression to G0-1. Reduction of 25% in Irinotecan dosing was 
applied for G3 non-hematological toxicity and G4 hematological toxicity in the previous cycle. 
The use of hemopoietic growth-factors for white and red cell lines was allowed when necessary.  
Study Schedule and Evaluations 
Screening assessments including medical history, physical examination
 
(including vital signs, 
height, weight and KPS), electrocardiogram
 
(ECG), chest X-ray and tumor measurements, based on 
the appropriate
 
imaging techniques (i.e. computed tomography scan) or physical examination, were 
conducted within
 
14 days before treatment initiation. Laboratory data including
 
complete blood 
count, blood chemistry and urinalysis were also
 
obtained.
 
During treatment, weekly assessments 
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included vital signs,
 
physical measurements, KPS, complete blood counts and blood
 
chemistry. For 
patients continuing treatment beyond 18 weeks,
 
these assessments were carried out at three-weekly 
intervals. Urinalysis,
 
chest X-ray, ECG and brain computed tomography scan were
 
performed if 
clinically indicated.
 
Patients could remain on treatment until disease progression (evaluated with the 
best instrumental exams applicable in case of metastatic lesions every one month of therapy) or the 
development of unacceptable toxicity or patient’s refusal. All tumor measurements were reviewed 
and confirmed by an independent
 
panel of radiologists and oncologists. 
 
Sample Size and Statistical Considerations 
The efficacy analysis was based on the intent-to-treat population. The primary end point was overall 
confirmed response rate. The Simon minimax two-stage design was used with early termination of 
the trial if a predetermined minimum level of activity was not observed after the first stage of 
accrual. The sample size calculation was performed to reject a 30% response rate in favour of a 
target response rate of 50%, with a significance level of 0.05 and a statistical power of 80%. The 
preliminary activity of cetuximab-based rechallenge was assessed through the accrual of 19 
patients. If there were ≤ 6 responses, accrual needed to be terminated. Otherwise 20 additional 
patients needed to be entered in the second stage to achieve a target sample size of 39 evaluable 
patients for tumor response. If more than 16 responses were observed in these 39 patients further 
assessment could be suggested. Time to progression was calculated from inclusion date to 
progression documented or death date. Treated patients would have been followed until disease 
progression. Safety was analyzed in all patients who received at least one dose of study medication. 
SPSS software (version 11.05, SPSS, Chicago) was used for statistical analysis. 
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RESULTS 
Patient Characteristics  
Demographic and other baseline characteristics of patient population are summarized in Table 1. 
From February 2007 to January 2010 a total of 39 patients were enrolled into the study. All patients, 
11 females/ 28 males, were assessable for treatment efficacy and safety. The median age of study 
population was 59 years (range: 44-82 years), all patients had an ECOG performance status of 0 or 
1, and 71.2% had two or more metastatic sites (28 patients) involving the liver (26 patients; 66.6%), 
the lung (14 patients; 35.9%) and the nodes (17 patients; 43.6%). Primary tumor site was colon in 
the 48.7% of patients, rectosigmoid junction in the 28.2% and rectum in the 25.3% of patients. 
Median number of therapeutic lines before study accrual, including original cetuximab containing 
regimen, was 4 (3-7). All patients were irinotecan refractory at the moment of the first cetuximab-
based therapy. Chemotherapy protocols associated during first cetuximab-based therapy were the 
following: irinotecan monotherapy (53.9%), FOLFIRI (46.1%). Best responses after first 
cetuximab-based therapy: 6 complete responses, 29 partial responses and 4 stable diseases lasting at 
least 6 months. Median time to progression with first treatment with cetuximab: 10 months (3-30) 
(Table 2). The median interval time between last cycle of first cetuximab-based therapy and first 
cycle of the following cetuximab retreatment was 6 months (2-12). All patients have been 
considered in progression at the moment of the study entry.  Chemotherapy protocols administrated 
after the first cetuximab-based therapy were the following : 5-fluorouracil-based therapy (17,9%), 
oxaliplatin-based therapy (51,3%); irinotecan-based therapy (7,7%), oxaliplatin-based therapy with 
bevacizumab (12,8%) and irinotecan-based therapy with bevacizumab (2,6%),   5-fluorouracil-
based therapy with bevacizumab (7,7%). Chemotherapy protocols associated during cetuximab 
rechallenge-based therapy were the same used during the first cetuximab-based therapy: irinotecan 
in 21 patients (53.9%) and FOLFIRI in the remaining 18 patients (46.1%). A total of 514 of weekly 
cetuximab-based cycles and a total of 94 bi-weekly cetuximab-based cycles have been 
administered. 
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Antitumor efficacy 
All patients enrolled in the study were assessable for antitumor efficacy. In the first stage of the 
study 6 partial responses and 1 complete response were obtained. For this reason we proceed to the 
second stage of the study. Considering all the included patients, the overall response rate according
 
to the IRC assessment was 53.8% (95% CI 39.1% to 63.7%) with 19 partial responses (48.7%) and 
2 complete responses (5.1%). Disease stabilization was obtained in 35.9% of patients (95% CI 
24.7% to 51.6%) for a clinical control rate of disease of 89.8%. Progression occurred in only 4 
patients (10.2%). The median time to progression was  6.6 months (95% C1: 4.1-9.1). 18 patients 
(46.1%) showed the same type of response (SD, PR or CR) during cetuximab retreatment when 
compared with the response obtained during the first cetuximab-based therapy, 2 patients (5.1%) 
has increased the quality of clinical result, transiting from a partial to a complete response and from 
stable disease to partial response respectively (Table 3). Both, stable disease lasting at least 6 
months and partial response during the first cetuximab-based therapy have been demonstrated to 
predict clinical benefit after cetuximab retreatment. The Kaplan-Meier curves for median time to 
progression are depicted in Figure 1.  
Safety results 
All patients enrolled in the study were assessable for safety. Most frequent grade3–4 adverse events 
were skin rash and diarrhea. Skin rash occurred in almost all patients (37 patients; 94.9%) and, as 
expected,  it was generally moderate to severe in intensity (grade 2: 41%; grade3: 38.5%; no grade 
4). It has been demonstrated a significant correlation between skin toxicity during first cetuximab 
therapy and cetuximab rechallenge (p= .01).  Diarrhea occurred in 22  (56.4%) patients and was 
grade 3–4 in only 3 (7.7%) and grade 1–2 in 19 (48.7) patients. Seven (18%) patients developed 
grade 3–4 neutropenia and no one febrile neutropenia. Dose delays were necessary in 17 patients 
(43.6%), mainly due to skin toxicity. Cetuximab dose adjustment was made in 5 (12.8%) patients 
because of skin toxicity. Six  (15.4%) patients required reduction of irinotecan dose, mainly because 
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of grade ≥2 diarrhea. No patient was hospitalized due to toxicities and no toxic death or cardiac and 
thromboembolic event occurred. Only 2 (5%) patients discontinued treatment due to toxicity.  
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DISCUSSION 
Data emerging from literature clearly pointed out that activating mutations of K-RAS, BRAF and 
PI3K predict lack of response to cetuximab or panitumumab therapy 
9,
 
27 ,
 
28
. Among these 
molecules, up to date only K-Ras has been validated for diagnostic applications, and the search for 
K-Ras mutations in codons 12 and 13 of exon 2, described in 25% to 45% of patients, is today 
mandatory in order to estabilish the best therapeutic option for metastatic colorectal cancer patients. 
The presence of K-Ras mutations in aberrant crypt foci
29
 and in preneoplastic lesions
30
 suggests that 
these event occur at a very early stage in human colorectal carcinogenesis. Moreover, despite the 
different lines of therapy administered, the K-Ras gene status seems to remain the same also in the 
advance phase of the disease, as shown by the high concordance of K-Ras testing results on the 
primary tumor and metastasis
31,32
. The acquisition of secondary mutations, which is a frequent 
phenomenon in many other cancer types, do not seem to play a major role in therapy-related 
resistance to anti-EGFR antibody treatment in metastatic colorectal cancer: in fact, the evaluation of 
K-Ras/BRAF status before and after anti-EGFR antibody treatment performed by Gattenlohner et 
al. is resulted highly concordant (95% for K-Ras, 100% for BRAF)
25
. However, approximately 5% 
to 10% of metastatic colorectal cancer show K-Ras molecular heterogeneity between primary, 
lymph node and distant metastases 
33
. Moreover, a recent study from Baldus et al. evaluated K-Ras, 
BRAF and PI3K gene status into the primary tumor, comparing the tumor center and the invasion 
fronts. The intratumoral heterogeneity of K-Ras, BRAF, and PIK3CA mutations was observed in 
8%, 1%, and 5% of primary tumors, respectively
34
. According to the evidence of intratumoral 
heterogeneity, the occurrence of a disease progression after the initial response in a wild-type K-Ras 
primary tumor could not be due to a late acquisition of the mutation rather to the progressive 
prevalence of a mutated clone, caused by a sort of  “cetuximab-driven mutated genotype 
acquisition” occurring during therapy. On the basis of these results and to our knowledge, we 
conducted the first phase II prospective trial evaluating the efficacy of a cetuximab rescue in K-Ras 
wild-type metastatic colorectal cancer patients who experienced a clinical benefit followed by a 
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progression with a previous cetuximab based therapy. After the failure of an irinotecan based first 
line therapy, the recourse to a cetuximab based therapy in K-Ras wild-type metastatic colorectal 
cancer patients, even without modifing K-Ras gene status, could lead to the destruction of wild-type 
cells and to the prevalence of mutated clones, which lead to a first progression of disease. A further 
line of therapy without cetuximab could restore K-Ras wild-type clones, which could constitute the 
major part of the tumor mass at the time of a following progression of disease. At this point, a 
rescue through a cetuximab based new line therapy may determine a further shrinkage of the 
disease. Results of this prospective study can be justified by this hypothesis. Moreover, the tumor 
cell entrance to epithelial to mesenchimal transition (EMT) or the reverse mesenchimal-to-epithelial 
transition (MET) may justify response or refractoriness, respectively, in patients retreated with 
Cetuximab. EMT is characterized by the combined loss of epithelial cell junction proteins such as 
E-cadherin and the gain of mesenchimal markers such as vimentin. Therefore, it is likely that the 
epithelial cells are more susceptible to EGFR-targeted therapies due to their activation of AKT 
primarily through EGFR-ErbB3. Mesenchymal cells activate AKT through alternative pathways 
like Integrin Linked Kinase (ILK)
35
 and are largely resistant to EGFR inhibitors. Cetuximab based 
therapy could lead during the time, after a first response, to activation of this alternative pathway, 
ILK-dependent, which allow the EMT. A further line without anti-EGFR therapy could 
downregulate this process restoring cetuximab sensitiveness. In fact we observed that rechallenge 
with the same cetuximab based therapy can achieve a new important clinical benefit delaying the 
progression of disease and improving the therapeutic options.   The present phase II trial is the first 
demonstration in literature of a potential clinical benefit deriving from a rechallenge with 
cetuximab-based therapy in K-Ras WT colorectal patients previously treated with the same anti-
EGFR-based protocol.  
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Table 1. Patient characteristics 
Characteristics No. of patients (%) 
Total number 39 (100) 
Male/Female 28/11 (71/29) 
Age (years) 
   median  
   range 
 
59 
44-82 
Performance Status 
     Median  
    Range 
 
0 
0-1 
Primary tumor site 
   Colon 
   Rectum 
   Rectosigmoid 
 
19 (49) 
9 (25) 
11 (29) 
Tumor differentiation  
   Well differentiated 
   Moderately differentiated 
   Poorly differentiated or undifferentiated  
 
4 (10) 
15 (39) 
20 (51) 
Median number of metastatic sites (range) 
     1 
     2-3 
     >3 
2 (1-6) 
11 (28) 
18 (46) 
10(26) 
Sites of metastases 
   Liver 
   Lung 
   Nodes 
   Local 
   Other 
 
26 (67) 
14 (36) 
17 (44) 
4 (10) 
8 (21) 
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Table 2. First Cetuximab-based therapy: characteristics 
Characteristics No. of patients (%) 
Total number 39 (100) 
Irinotecan refractory 39 (100) 
Protocol of association  
  Irinotecan monotherapy 
  FOLFIRI 
 
21 (54) 
18 (46) 
Best Response 
  Stable Disease (> 6 months) 
  Partial Response 
  Complete Response 
 
4 (10) 
29 (74) 
6 (15) 
Median Time To Progression- months (range) 10 (3-30) 
Median number of lines before cetuximab 
retreatment (range) 
4 (3-7) 
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Table 3. Clinical response after first cetuximab-based therapy and second cetuximab-based therapy 
in 39 patients 
 
 
Best response 1st 
Cetuximab 
 
Best response 
rechallenge 
# patients Total # (%) 
PR 
CR 
 
CR 
1 
1 
 
2 (5) 
SD 
PR 
CR 
 
PR 
1 
14 
4 
 
19(49)  
SD 
PR 
CR 
 
SD 
3 
10 
1 
 
14 (36) 
PR PD 4 4 (10) 
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4.146 – 9.0546.0 months
95% CIMedian value
 
Figure 1. Kaplan-Meyer curve for Time-to-progression. 
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